[{"orgOrder":0,"company":"Famy Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Pimecrolimus","moa":"FK506-binding protein 1A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Famy Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Famy Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Famy Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Famy Life Sciences","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Famy Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.28000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Famy Life Sciences \/ Viatris","highestDevelopmentStatusID":"10","companyTruncated":"Famy Life Sciences \/ Viatris"},{"orgOrder":0,"company":"Famy Life Sciences","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Famy Life Sciences","amount2":0.28000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.28000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Famy Life Sciences \/ Viatris","highestDevelopmentStatusID":"10","companyTruncated":"Famy Life Sciences \/ Viatris"}]

Find Clinical Drug Pipeline Developments & Deals by Famy Life Sciences

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : Pimecrolimus is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Blepharitis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 06, 2024

                          Lead Product(s) : Pimecrolimus

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : With the combination of Viatris' global commercial footprint, R&D and regulatory capabilities, along with Famy Life Sciences' Phase III-ready pipeline, the Company believes it has the foundation to create a leading global ophthalmology franchise.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          January 03, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase III

                          Sponsor : Viatris

                          Deal Size : $280.0 million

                          Deal Type : Acquisition

                          blank

                          03

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : With the combination of Viatris' global commercial footprint, R&D and regulatory capabilities, along with Famy Life Sciences' Phase III-ready pipeline, the Company believes it has the foundation to create a leading global ophthalmology franchise.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          November 07, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase III

                          Sponsor : Viatris

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank